| Active substance | fedratinib |
| Holder | BMS |
| Status | Running |
| Indication | treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis have been treated with ruxolitinib. |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 08/08/2022 |